GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorepand atezolizumab –safety and preliminary response results
Collienne, Maike et al, Previously presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022; June 29 – July 2, 2022